Numerous molecular mechanisms are being examined in an attempt to discover disease-modifying drugs to slow down the underlying neurodegeneration in Alzheimer’s disease.Recent studies have shown the beneficial effects...Numerous molecular mechanisms are being examined in an attempt to discover disease-modifying drugs to slow down the underlying neurodegeneration in Alzheimer’s disease.Recent studies have shown the beneficial effects of epidermal growth factor receptor inhibitors on the enhancement of behavioral and pathological sequelae in Alzheimer’s disease.Despite the promising effects of epidermal growth factor receptor inhibitors in Alzheimer’s disease,there is no irrefutable neuroprotective evidence in well-established animal models using epidermal growth factor receptor inhibitors due to many un-explored downstream signaling pathways.This caused controversy about the potential involvement of epidermal growth factor receptor inhibitors in any prospective clinical trial.In this review,the mystery beyond the under-investigation of epidermal growth factor receptor in Alzheimer’s disease will be discussed.Furthermore,their molecular mechanisms in neurodegeneration will be explained.Also,we will shed light on SARS-COVID-19 induced neurological manifestations mediated by epidermal growth factor modulation.Finally,we will discuss future perspectives and under-examined epidermal growth factor receptor downstream signaling pathways that warrant more exploration.We conclude that epidermal growth factor receptor inhibitors are novel effective therapeutic approaches that require further research in attempts to be repositioned in the delay of Alzheimer’s disease progression.展开更多
Catalysts using α-FeOOH nanoparticles as the active ingredient were testedby a microreactor-chromatography assessing apparatus at atmospheric pressure between 25 and 60 ℃with a gas hourly space velocity of 10,000 h^...Catalysts using α-FeOOH nanoparticles as the active ingredient were testedby a microreactor-chromatography assessing apparatus at atmospheric pressure between 25 and 60 ℃with a gas hourly space velocity of 10,000 h^(-1), while the removal performance of H_2S withcatalysts was investigated using the thermal gravimetric method. The results show that the catalystsare highly active for COS hydrolysis at low temperatures (≤60 ℃) and high gas hourly spacevelocity, and the highest activity can reach 100%. The catalyst is particularly stable for 12 h, andno deactivation is observed. Nanoparticle α-FeOOH prepared using hydrated iron sulfate showshigher COS hydrolysis activity, and the optimum calcination temperature for the catalyst is 260 ℃.In addition, the catalysts can remove COS and H_2S simultaneously, and 60 ℃ is favorable for theremoval of H_2S. The compensation effect exists in nanoparticle-based catalysts.展开更多
文摘Numerous molecular mechanisms are being examined in an attempt to discover disease-modifying drugs to slow down the underlying neurodegeneration in Alzheimer’s disease.Recent studies have shown the beneficial effects of epidermal growth factor receptor inhibitors on the enhancement of behavioral and pathological sequelae in Alzheimer’s disease.Despite the promising effects of epidermal growth factor receptor inhibitors in Alzheimer’s disease,there is no irrefutable neuroprotective evidence in well-established animal models using epidermal growth factor receptor inhibitors due to many un-explored downstream signaling pathways.This caused controversy about the potential involvement of epidermal growth factor receptor inhibitors in any prospective clinical trial.In this review,the mystery beyond the under-investigation of epidermal growth factor receptor in Alzheimer’s disease will be discussed.Furthermore,their molecular mechanisms in neurodegeneration will be explained.Also,we will shed light on SARS-COVID-19 induced neurological manifestations mediated by epidermal growth factor modulation.Finally,we will discuss future perspectives and under-examined epidermal growth factor receptor downstream signaling pathways that warrant more exploration.We conclude that epidermal growth factor receptor inhibitors are novel effective therapeutic approaches that require further research in attempts to be repositioned in the delay of Alzheimer’s disease progression.
文摘Catalysts using α-FeOOH nanoparticles as the active ingredient were testedby a microreactor-chromatography assessing apparatus at atmospheric pressure between 25 and 60 ℃with a gas hourly space velocity of 10,000 h^(-1), while the removal performance of H_2S withcatalysts was investigated using the thermal gravimetric method. The results show that the catalystsare highly active for COS hydrolysis at low temperatures (≤60 ℃) and high gas hourly spacevelocity, and the highest activity can reach 100%. The catalyst is particularly stable for 12 h, andno deactivation is observed. Nanoparticle α-FeOOH prepared using hydrated iron sulfate showshigher COS hydrolysis activity, and the optimum calcination temperature for the catalyst is 260 ℃.In addition, the catalysts can remove COS and H_2S simultaneously, and 60 ℃ is favorable for theremoval of H_2S. The compensation effect exists in nanoparticle-based catalysts.
